fbpx

molecules of the month

camlipixant

oral BID P2X3 receptor antagonist

Ph. III for first-line treatment of refractory chronic cough

non-competitive homotrimeric receptor antagonist; discovery not disclosed

GSK acquisition announcement, April 18, 2023

AstraZeneca Canada/NeoMed (adMare)/Bellus Health/GSK

camlipixant, P2X3, oral BID P2X3 receptor antagonist, Ph. III for first-line treatment of refractory chronic cough, non-competitive homotrimeric receptor antagonist; discovery not disclosed, GSK acquisition announcement, April 18, 2023, ASTRAZENECA/NEOMED/BELLUS HEALTH/GSK
8 mins read

A P2X3-selective antagonist for chronic cough without taste effects. Camlipixant is an orally administered antagonist of the ATP-sensing P2X3 homotrimeric receptor ion channel, originated by AstraZeneca AB and assigned to the Canadian NEOMED Institute (now adMare), and developed by BELLUS Health (Canada), for the treatment of chronic cough. Chronic cough remains difficult to treat - the last FDA-approved anti-tussive, dextromethorphan, was first approved in 1958 and has demonstrated limited clinical efficacy. While Merck‚Äôs gefapixant (AF-219/RO-4926219) was recently rejected by the FDA for concerns about efficacy, it is approved in Japan and P2X3 receptor antagonists are ultimately expected to be marketed worldwide in a range of indications based on data so far. In contrast to gefapixant, which demonstrated efficacy in earlier…


request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.


already a member? log in: